Application of MiniPDX® in Drug R&D: Fast, Predictive and Translational
Traditional PDX models offer strong clinical fidelity but require 4 to 6 months to generate results, making them impractical for early-stage screening or time-sensitive development decisions. MiniPDX® changes the game, delivering in vivo drug-sensitivity data in just 7 days, while maintaining a strong correlation with both PDX models and clinical outcomes. It can be used across every major phase of drug development:
| Drug Development Phase | MiniPDX Benefit |
|---|---|
| Lead Optimization | Rapid in-vivo screening of drug candidates to prioritize top performers |
| Candidate Development | Model screening using MiniPDX® identifies the right indications and models for used in downstream testing |
| Clinical Preparations | Clinical MiniPDX® with fresh patient tissues, combined with omics analysis can identify predictive biomarkers |
Applications of MiniPDX
1. Lead Optimization: Real world biology for better
candidate selection
In early-stage drug development, selecting the right compound to advance is critical-but traditional in vitro methods often fall short in predicting in vivo performance. MiniPDX® provides a powerful alternative, enabling researchers to rapidly screen multiple candidates in a physiologically relevant, in vivo tumor environment—within just 7 days.
| Traditional Model | Limitations |
|---|---|
| 2D cell cultures | Lack 3D structure, tumor microenvironment, and in vivo pharmacokinetics. Dosing mechanisms not representative of real life application. |
| 3D spheroids / organoids | Lack vasculature and immune cell components. Do not recapitulate systemic drug exposure |
| Cell Lines (CDX models) | Genetically adapted to culture, genetically drifted from primary tumors. Low translational value. |
- Candidate down-selection: Screen 5–10 preclinical compounds in parallel, identify top responders.
- Program prioritization: Compare pipeline molecules to determine which deserves advancement.
- Formulation testing: Evaluate alternate drug formulations or dosage in a clinically relevant setting.
2. Candidate Development: Enabling Early, Informed Decisions
If you have a candidate compound and ready for in-vivo validation, MiniPDX® is uniquely suited as a bridge to more robust PDX testing. Fast turnaround and low sample requirements enable informed decisions without spending significant resources. Here’s several ways it can be used:
Use case 1: Indication Selection & Expansion
- Use MiniPDX® across multiple tumor types (basket trials) or genetic subtypes (umbrella trials) to identify where the candidate performs best
- Pinpoint responder populations-especially in cancers with no clear first-line option
- Rapidly test for off-label or repurposing potential in rare indications
Example: A compound originally developed for colorectal cancer shows strong MiniPDX® responses in MSI-high endometrial tumors—opening a new indication path with lower competition.
Use case 2: Screen PDX Models for IND-enabling Studies
- Choose from LIDE’s extensive PDX library-categorized by indication, mutation, drug resistance, or subtype
- Match your candidate to patient-derived tumors with relevant genetic backgrounds
- Evaluate drug responses in realistic tumor microenvironments to identify models for more robust IND-enabling studies
Example: A PARP inhibitor is tested in MiniPDX® models carrying BRCA1, BRCA2, and ATM mutations to determine which models and mutations are most responsive, to be used in larger IND-enabling studies.
Use case 3: Benchmarking Against Standard of Care (SOC)
- Directly compare your candidate’s efficacy to existing SOC drugs or combinations
- Evaluate relative tumor kill, resistance profiles, and combination synergies
- Establish competitive differentiation for investor decks or pipeline go/no-go decisions
Example: A company tests its novel EGFR inhibitor versus osimertinib and sees superior tumor inhibition in T790M+ lung cancer MiniPDX® models-supporting its pitch for additional funding and development.
Use case 4: Dosing Insights
- Test multiple doses and schedules (e.g., daily vs. every 2 days, single vs. split dosing) in parallel
- Identify the minimum effective dose and flag toxicity early (via cell viability and body weight changes.
Example: A biotech uses MiniPDX® to test three concentrations of a kinase inhibitor across two schedules. Within 7 days, they identify a dose-schedule combo that balances potency and tolerability for IND-enabling studies.
3. Clinical Preparations: Biomarker Discovery and Patient Stratification
Designing a successful clinical trial requires more than a promising compound-it demands data-driven insights into the right dose, population, and biomarker strategy. MiniPDX® accelerates this process by enabling rapid functional profiling of drug responses using fresh patient samples, and when paired with multi-omics analysis, offers a powerful tool for guiding patient selection and trial design.
LIDE’s MiniPDX® platform is uniquely positioned to support translational and clinical teams during trial planning. By implanting patient-derived tumor cells and applying systemic dosing regimens, MiniPDX® reveals which patients are most likely to benefit from a therapy-and why.
- Capture RNA, DNA, and protein expression data from the same tumor sample
- Identify predictive biomarkers based on drug sensitivity profiles
- Understand mechanisms of resistance in non-responders
- Stratify patients by mutation, expression signature, or immune profile
Watch LIDE’s CEO discuss how MiniPDX is used in both the clinic and preclinical setting: